Views & Analysis A new age: the real-world development pathway Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Debates & Insight Sponsored OMA at NICE: Unlocking Access One Year On A new report by health economist Leela Barham examines how NICE’s Office for Market Access has progressed after a year in operation.
Views & Analysis Rare diseases and orphan drugs need digital innovation mHealth tech can provide longer-term monitoring for clinical trials.
Views & Analysis The PPRS medicines pricing scheme: is it working for both si... The PPRS has now reached the half-way stage - a look at the stats so far.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
News UK must draw up post-Brexit pharma strategy Big pharma could take its money elsewhere post Brexit, report warns.
News GBL joins CVC in €10.7bn takeover bid for Recordati A consortium of investors has made a €10.7bn offer to take Italian pharma Recordati private, but some analysts are sceptical the deal will go through.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
